GlobeNewswire

World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer

Del

TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) featured some of the year’s most innovative research in both small cell and non-small cell lung cancer. Frances Shepherd, M.D., FRCPC, WCLC honorary chair, medical oncologist at Princess Margaret Cancer Centre and former president of the IASLC (2005-2007), opened with the practice-changing importance of data shared this morning at the 2018 Presidential Symposium. Dr. Shepherd continued with background on the current inoperability and low cure rate of Stage III lung cancers, which comprise 1/3 of all lung cancers. Ground breaking data presented during today’s symposium demonstrated an advancement in disease treatment not seen for many years.

PACIFIC study shows durvalumab improves overall survival in patients with unresectable non-small cell lung cancer without progression after chemoradiotherapy
Recent findings from the PACIFIC trial found that durvalumab demonstrates statistically significant and clinically meaningful improvement in overall survival (OS) compared with placebo for patients with Stage III, unresectable non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy (CRT).

According to Scott J. Antonia, M.D., Ph.D., department chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa and Professor of Oncologic Sciences at the University of South Florida College of Medicine, these results are significant, as PACIFIC is the first trial to show a survival advantage following CRT in this patient population.

“Results of PACIFIC provide compelling evidence for the unprecedented benefit of durvalumab treatment as the standard of care in this patient population,” said Dr. Antonia. “Durvalumab offers the first major advance in this disease setting in many years, offering new hope to patients with Stage III, unresectable NSCLC without progression after CRT.”

Read the full press release here.

Interim analysis of ALTA-1L demonstrates potential for brigatinib as first-line treatment option for ALK-positive non-small cell lung cancer
An interim analysis of the ALTA-1L study provided the first comparative data on the efficacy and safety of brigatinib versus crizotinib, the first-line standard of care comparator, in patients with anaplastic lymphoma kinase (ALK) inhibitor-naive ALK+ non-small cell lung cancer (NSCLC).

Lead investigator Ross Camidge, M.D., Ph.D., Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center, and team found one-year post-treatment, 67 percent of patients treated with brigatinib remained progression-free compared to 43 percent of those treated with crizotinib, and the risk of progression or death was reduced by 51 percent with brigatinib compared to crizotinib.

“Interim data shows brigatinib is set to become a first-line treatment option for ALK+ lung cancer,” said Dr. Camidge. “Even with only nine to 11 months of follow-up, the efficacy of brigatinib is clearly superior to crizotinib.”

Read the full press release here.

NELSON study shows CT screening for nodule volume management reduces lung cancer mortality by over fifty percent
Recent findings from Europe’s largest running lung cancer screening trial, the NELSON study, demonstrate that the use of computed tomography (CT) screening with a unique nodule management protocol led to a 26 percent reduction in deaths among lung cancer patients at eight years of study follow-up.

Harry J. De Koning, M.D., Ph.D., professor of Public Health & Screening Evaluation, Erasmus Medical Center, Rotterdam, Netherlands, and team initiated the study to assess the effect of CT screening, in combination with increasing screening intervals, on lung cancer mortality.

“These findings show that CT screenings are an effective way to assess and manage nodule volume in lung cancer patients, often leading to detection of suspicious nodules and subsequent surgical intervention, and can positively impact survival rates,” said Dr. De Koning. “These results can be used to inform and direct ongoing medical follow up and intervention for lung cancer patients.”

Read the full press release here.

Atezolizumab improves outcomes for small cell lung cancer when added to standard-of-care treatment
The IMpower133 study successfully met its co-primary endpoints, demonstrating that adding 1L atezolizumab to standard carboplatin and etoposide prolonged overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC), as compared to carboplatin and etoposide treatment alone.

According to presenter Stephen V. Liu, M.D., associate professor of medicine at Georgetown University and a member of the trial steering committee, these findings have the potential to change the current treatment landscape for ES-SCLC.

“The standard of care for extensive-stage small cell lung cancer has been unchanged for decades, which has contributed to unacceptably poor outcomes,” said Dr. Liu. “This is the first study in 30 years to show a significant improvement in survival in the first line treatment of this highly lethal disease. This is an exciting time in oncology, and we are thrilled to finally see real progress in the SCLC space.”

Read the full press release here.

LUME-Meso study shows nintedanib plus pemetrexed/cisplatin does not improve progression-free or overall survival in patients with malignant pleural mesothelioma of epithelioid subtype
Findings from the LUME-Meso study demonstrate that triple angiokinase inhibitor nintedanib combined with standard-of-care pemetrexed/cisplatin does not impact progression-free survival (PFS) and overall survival (OS) for unresectable malignant pleural mesothelioma (MPM) patients with epithelioid histology.

When Phase II data of LUME-Meso showed patients with epithelioid histology derived the greatest benefit from nintedanib added to pemetrexed/cisplatin in terms of improved PFS versus placebo and a trend towards improved OS, Giorgio V. Scagliotti, M.D., Ph.D., of the University of Turin’s Department of Oncology and S. Luigi Hospital, president of the International Association for the Study of Lung Cancer (IASLC), and team amended the Phase III protocol to focus solely on this subgroup.

“Unfortunately, the Phase III results of LUME-Meso did not confirm that nintedanib in combination with pemetrexed/cisplatin prolongs patients’ lives,” said Dr. Scagliotti. “However, the trial reaffirms the need for solid confirmatory studies, adequately sized, to challenge the standard of care in advanced malignant mesothelioma.”

Read the full press release here.

Livestreams of the daily press conferences are available here.

About the WCLC

The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contacts:
Lisa Rivero  Becky Bunn, MSc
Vice President Public Relations Manager
lrivero@jpa.com| +1 617-657-1305 Becky.Bunn@IASLC.org | +1 720-254-9509

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Constellation Brands CEO Bill Newlands Signs CEO Action for Diversity & Inclusion Pledge20.6.2019 15:00:00 CESTPressemelding

VICTOR, N.Y., June 20, 2019 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that that Bill Newlands, president and chief executive officer, is joining CEO Action for Diversity & Inclusion™ - the largest CEO-driven business commitment to advance diversity and inclusion within the workplace. The CEO Action for Diversity & Inclusion recognizes that change often happens when there’s support at the executive level. More than 600 CEOs of the world’s leading companies and business organizations are leveraging their voices to advance diversity and inclusion in the workplace by placing individual accountability on all—leaders and employees—to create inclusive environments. “At Constellation, we work hard to foster an inclusive culture that is characterized by diversity in background and thought, and that reflects our consumers and the communities where we live and work,” said Newlands. “Signing the CEO Action for Diversit

Radient Technologies Inc. Provides Update on Progress of Cannabis and Hemp Extraction Facilities and Issues Shares for Services20.6.2019 13:30:00 CESTPressemelding

EDMONTON, Alberta, June 20, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce it has awarded the mandate for the second phase of the construction of its Edmonton III manufacturing facility to Fillmore Construction Management Inc. (“Fillmore”). Construction is well underway, with footings and foundation work having been completed, and the structural component of the building now in progress and on schedule. Fillmore was selected by Radient due to its extensive previous experience developing food processing and GMP approved manufacturing plants. Edmonton III is Radient’s expanded capacity cannabis and hemp processing line that is expected to have a total annual throughput capacity of 280,000 kg/year of cannabis, and 2,800,000 kg/year of hemp upon completion in calendar 2020. Radient completed its first commercial extraction run for Aurora Cannabis Inc. (“Aurora”) (TSX: ACB; NYSE: ACB) in May 2019 at its

TeraRecon Receives First-of-Kind FDA Determination20.6.2019 11:00:00 CESTPressemelding

DURHAM, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- Advanced visualization and artificial intelligence (AI) technology provider, TeraRecon, today announced it has successfully completed an FDA regulatory review of its Northstar™ AI Results Explorer, for which the technology and the determination are both firsts-of-kind in the medical imaging industry. Northstar is designed to work alongside the company’s EnvoyAI™ interoperability platform which includes FDA-cleared 3rd party content listed on its EnvoyAI Exchange marketplace. The Northstar determination letter reinforces the company’s commitment to regulatory and quality standards along with transparency in the field of medical imaging artificial intelligence. The Northstar AI Results Explorer provides an engaging physician user experience which can be integrated into the clinical systems already used throughout the health enterprise. Now with full commercial availability, Northstar can provide physicians an important way to accept, reject

Appian Named A Leader in Digital Process Automation for Deep Deployments Report by Independent Research Firm19.6.2019 16:28:00 CESTPressemelding

RESTON, Va, June 19, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) today announced it has been named a leader in “The Forrester Wave™: Software For Digital Process Automation For Deep Deployments, Q2 2019” report (“DPA Deep”). In Forrester’s four market segments for rapid application development, DPA Deep platforms “excel at the high end of process complexity but may also be the right solution to meet the needs for a wide-deployment, low-code standard” in an organization. In Forrester’s evaluation, Appian tied for the top score in the Current Offering category (including criteria for user experience development tools; process and flow design; digital decisioning, and robotic process automation). Appian also received among the second-highest scores in the Strategy category (including criteria like vision and strategy, commercial model, partners and training, community, and marketplace). The report notes that “Appian is a low-code vendor that thrives in complex process environments.” Th

Seaborn Networks announces new IP & Ethernet Services for Brazil and U.S. market19.6.2019 14:30:00 CESTPressemelding

BOSTON, June 19, 2019 (GLOBE NEWSWIRE) -- Seaborn Networks (“Seaborn”), a leading developer-owner-operator of subsea fiber optic cable systems, today announced that it will be delivering industry leading performance with new IP Service offerings comprising of diverse Ethernet Service and IP Service solutions addressing the market’s demand for rapidly deployed and highly stable global Ethernet & IP based needs between North and South America. IP Service offerings will include IP Transit, Remote Peering, Cloud Connect and Enterprise DIA solutions. Seaborn’s IP Services are offered under a minimal commitment with the ability to utilize additional bandwidth on a pay-as-you-use basis. Seaborn’s Ethernet Service offerings include E-Line, E-LAN and E-Tree capabilities with options for protected service depending on the Class of Service (CoS) selected. Industry leading SLA’s are provided on all IP and Ethernet services. “In today’s fast paced, highly complex communications environment, busines

Standard Lithium Announces Positive Preliminary Economic Assessment and Upgrading of Mineral Resource at Its Southern Arkansas Lithium Brine Project19.6.2019 09:00:00 CESTPressemelding

VANCOUVER, British Columbia, June 19, 2019 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to announce the results of a Preliminary Economic Assessment (PEA) of its 150,000 acre project in the south-central region of Arkansas, USA (the “Property”). The PEA considers the production of battery-quality lithium carbonate through a phased build-out to a total 20,900 tonnes per annum (tpa) from the contemplated joint venture with Lanxess Corp. (see press release dated November 12, 2018) at their three-operating bromine-processing plants. The PEA also includes the reclassification of the existing mineral resource to an Indicated category. The PEA was prepared by Advisian, the consulting arm of WorleyParsons Canada Services Ltd (Worley), a world-leading integrated engineering firm with extensive experience in the design and construction of chemical plants and lithium brine processing projects around the globe. Ke